or Try an Advanced Search...

    Technical Analysis for TCON - TRACON Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 0.03 -31.40% -0.01
    TCON closed down 19.48 percent on Monday, November 11, 2024, on 6 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical TCON trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish -31.40%
    NR7 Range Contraction -31.40%
    Narrow Range Bar Range Contraction -31.40%
    New 52 Week Low Weakness -31.40%
    Wide Bands Range Expansion -31.40%
    Down 3 Days in a Row Weakness -31.40%
    Oversold Stochastic Weakness -31.40%
    New 52 Week Closing Low Bearish -44.76%
    Narrow Range Bar Range Contraction -44.76%
    Doji - Bullish? Reversal -44.76%
    Older End-of-Day Signals for TCON ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 2 hours ago
    Outside Day about 2 hours ago
    Down 5% about 2 hours ago
    Down 3% about 2 hours ago
    Up 5% about 2 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    TCON Chart by TradingView
    Basic chart:

    Profile

    TRACON Pharmaceuticals, Inc. Description

    TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration, and fibrotic diseases. Its lead product candidate is TRC105, which is in Phase II clinical trials for oncology indications, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, and hepatocellular carcinoma. The company is planning for clinical trials of TRC105, including a Phase II clinical trial in patients with breast cancer and hepatocellular carcinoma, a Phase I clinical trial in patients with colorectal cancer, and a Phase I clinical trial in patients with lung cancer, as well as conducting preclinical studies of TRC105 in AMD. In addition, the company product candidates comprise TRC205, an anti-endoglin antibody that is in preclinical stage for the treatment of fibrotic diseases; and TRC102, a small molecule, which is in clinical development for the treatment of lung cancer and glioblastoma. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Drugs Clinical Development Breast Cancer Clinical Trial Treatment Of Breast Cancer Colorectal Cancer Macular Degeneration Blastoma Glioblastoma Lung Cancer Sarcoma Carcinoma Targeted Therapy Hepatocellular Carcinoma Age Related Macular Degeneration Renal Cell Carcinoma Soft Tissue Sarcoma Fibrotic Disease Therapeutics For Cancer Transgene Sa

    Is TCON a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 30 TRACON Pharmaceuticals to wind down operations
    Jul 30 TRACON Pharmaceuticals Announces it Will Wind Down Operations
    Jul 2 Tracon mulls strategic options after sarcoma drug fails Phase II trial
    Jul 1 TRACON ends development of envafolimab, exploring strategic options
    Jul 1 TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
    Jun 11 TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
    See more TCON news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.746
    52 Week Low 0.035
    Average Volume 157,826
    200-Day Moving Average 3.26
    50-Day Moving Average 1.18
    20-Day Moving Average 0.75
    10-Day Moving Average 0.16
    Average True Range 0.20
    RSI (14) 25.93
    ADX 33.89
    +DI 17.25
    -DI 46.55
    Chandelier Exit (Long, 3 ATRs) 1.18
    Chandelier Exit (Short, 3 ATRs) 0.63
    Upper Bollinger Bands 1.98
    Lower Bollinger Band -0.47
    Percent B (%b) 0.21
    BandWidth 324.58
    MACD Line -0.39
    MACD Signal Line -0.33
    MACD Histogram -0.0558
    Fundamentals Value
    Market Cap 1.34 Million
    Num Shares 31.1 Million
    EPS -0.44
    Price-to-Earnings (P/E) Ratio -0.10
    Price-to-Sales 0.71
    Price-to-Book 11.83
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.06
    Resistance 3 (R3) 0.05 0.05 0.05
    Resistance 2 (R2) 0.05 0.05 0.05 0.05
    Resistance 1 (R1) 0.05 0.04 0.05 0.05 0.05
    Pivot Point 0.04 0.04 0.04 0.04 0.04
    Support 1 (S1) 0.04 0.04 0.04 0.04 0.03
    Support 2 (S2) 0.03 0.04 0.03 0.03
    Support 3 (S3) 0.03 0.03 0.03
    Support 4 (S4) 0.03